Nitric Oxide Synthetic Pathway in Red Blood Cells Is Impaired in Coronary Artery Disease

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Eligini, Sonia ^a   Porro, Benedetta ^a   Lualdi, Alessandro ^a,b   Squellerio, Isabella ^a   Veglia, Fabrizio ^a   Chiorino, Elisa ^a   Crisci, Mauro ^a   Garlaschè, Anna ^a   Giovannardi, Marta ^a   Werba, Josè Pablo ^a   Tremoli, Elena ^a,b   Cavalca, Viviana ^a,b  

^a CENTRO CARDIOLOGICO MONZINO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE; ARGININE; ASYMMETRIC DIMETHLARGININE; GLUTATHIONE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITROGEN ARGININE N 15; NITROGEN CITRULLINE N 15; RADIOISOTOPE; SYMMETRIC DIMETHLARGININE; UNCLASSIFIED DRUG;

AGED; AMINO ACID METABOLISM; ARTICLE; BIOSYNTHESIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ENZYME ACTIVITY; ERYTHROCYTE; EX VIVO STUDY; FEMALE; HEART MUSCLE ISCHEMIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; INTRACELLULAR SIGNALING; MALE; OBSERVATIONAL STUDY; OXIDATIVE STRESS; PLASMA; PROTEIN EXPRESSION; STABLE ANGINA PECTORIS; TANDEM MASS SPECTROMETRY;

AGED; ARGININE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORONARY ARTERY DISEASE; ERYTHROCYTES; FEMALE; GLUTATHIONE; HUMANS; MALE; MIDDLE AGED; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXIDATIVE STRESS; TANDEM MASS SPECTROMETRY;

EID: 84881097762     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066945     Document Type: Article

References (51)

1. Moncada S, Palmer RM, Higgs EA, (1991) Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 43: 109-142.
2. Radomski MW, Palmer RM, Moncada S, (1987) Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 2: 1057-1058.
3. Bode-Boger SM, Scalera F, Kielstein JT, Martens-Lobenhoffer J, Breithardt G, et al. (2006) Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease. J Am Soc Nephrol 17: 1128-1134.
4. Huang KT, Han TH, Hyduke DR, Vaughn MW, Van Herle H, et al. (2001) Modulation of nitric oxide bioavailability by erythrocytes. Proc Natl Acad Sci U S A 98: 11771-11776.
5. Kleinbongard P, Schulz R, Rassaf T, Lauer T, Dejam A, et al. (2006) Red blood cells express a functional endothelial nitric oxide synthase. Blood 107: 2943-2951.
6. Yokoro M, Suzuki M, Murota K, Otsuka C, Yamashita H, et al. (2012) Asymmetric dimethylarginine, an endogenous NOS inhibitor, is actively metabolized in rat erythrocytes. Biosci Biotechnol Biochem 76: 1334-1342.
7. Omodeo-Sale F, Cortelezzi L, Vommaro Z, Scaccabarozzi D, Dondorp AM, (2010) Dysregulation of L-arginine metabolism and bioavailability associated to free plasma heme. Am J Physiol Cell Physiol 299: C148-154.
8. Billecke SS, Kitzmiller LA, Northrup JJ, Whitesall SE, Kimoto M, et al. (2006) Contribution of whole blood to the control of plasma asymmetrical dimethylarginine. Am J Physiol Heart Circ Physiol 291: H1788-1796.
9. Davids M, van Hell AJ, Visser M, Nijveldt RJ, van Leeuwen PA, et al. (2012) Role of the human erythrocyte in generation and storage of asymmetric dimethylarginine. Am J Physiol Heart Circ Physiol 302: H1762-1770.
10. Jensen FB, (2009) The dual roles of red blood cells in tissue oxygen delivery: oxygen carriers and regulators of local blood flow. J Exp Biol 212: 3387-3393.
11. Chen LY, Mehta JL, (1998) Evidence for the presence of L-arginine-nitric oxide pathway in human red blood cells: relevance in the effects of red blood cells on platelet function. J Cardiovasc Pharmacol 32: 57-61.
12. Bor-Kucukatay M, Meiselman HJ, Baskurt OK, (2005) Modulation of density-fractionated RBC deformability by nitric oxide. Clin Hemorheol Microcirc 33: 363-367.
13. Ulker P, Gunduz F, Meiselman HJ, Baskurt OK, (2012) Nitric oxide generated by red blood cells following exposure to shear stress dilates isolated small mesenteric arteries under hypoxic conditions. Clin Hemorheol Microcirc.
14. Cortese-Krott MM, Rodriguez-Mateos A, Sansone R, Kuhnle GG, Thasian-Sivarajah S, et al. (2012) Human red blood cells at work: identification and visualization of erythrocytic eNOS activity in health and disease. Blood 120: 4229-4237.
15. Shemyakin A, Kovamees O, Rafnsson A, Bohm F, Svenarud P, et al. (2012) Arginase inhibition improves endothelial function in patients with coronary artery disease and type 2 diabetes mellitus. Circulation 126: 2943-2950.
16. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T, (2001) Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 104: 2673-2678.
17. Cavalca V, Veglia F, Squellerio I, Marenzi G, Minardi F, et al. (2009) Glutathione, vitamin E and oxidative stress in coronary artery disease: relevance of age and gender. Eur J Clin Invest 39: 267-272.
18. Squellerio I, Tremoli E, Cavalca V, (2011) Quantification of arginine and its metabolites in human erythrocytes using liquid chromatography-tandem mass spectrometry. Anal Biochem 412: 108-110.
19. Morris CR, Kato GJ, Poljakovic M, Wang X, Blackwelder WC, et al. (2005) Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA 294: 81-90.
20. Sourij H, Meinitzer A, Pilz S, Grammer TB, Winkelmann BR, et al. (2011) Arginine bioavailability ratios are associated with cardiovascular mortality in patients referred to coronary angiography. Atherosclerosis 218: 220-225.
21. Jung C, Gonon AT, Sjoquist PO, Lundberg JO, Pernow J, (2010) Arginase inhibition mediates cardioprotection during ischaemia-reperfusion. Cardiovasc Res 85: 147-154.
22. Fukushima T, Nixon JC, (1980) Analysis of reduced forms of biopterin in biological tissues and fluids. Anal Biochem 102: 176-188.
23. Squellerio I, Caruso D, Porro B, Veglia F, Tremoli E, et al. (2012) Direct glutathione quantification in human blood by LC-MS/MS: comparison with HPLC with electrochemical detection. J Pharm Biomed Anal 71: 111-118.
24. Harris C, Hansen JM, (2012) Oxidative stress, thiols, and redox profiles. Methods Mol Biol 889: 325-346.
25. Asensi M, Sastre J, Pallardo FV, Lloret A, Lehner M, et al. (1999) Ratio of reduced to oxidized glutathione as indicator of oxidative stress status and DNA damage. Methods Enzymol 299: 267-276.
26. Kulier A, Levin J, Moser R, Rumpold-Seitlinger G, Tudor IC, et al. (2007) Impact of preoperative anemia on outcome in patients undergoing coronary artery bypass graft surgery. Circulation 116: 471-479.
27. Sabatine MS, Morrow DA, Giugliano RP, Burton PB, Murphy SA, et al. (2005) Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation 111: 2042-2049.
28. Reiter CD, Wang X, Tanus-Santos JE, Hogg N, Cannon RO 3rd, et al. (2002) Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 8: 1383-1389.
29. Lu TM, Chung MY, Lin MW, Hsu CP, Lin SJ, (2011) Plasma asymmetric dimethylarginine predicts death and major adverse cardiovascular events in individuals referred for coronary angiography. Int J Cardiol 153: 135-140.
30. Schulze F, Lenzen H, Hanefeld C, Bartling A, Osterziel KJ, et al. (2006) Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study. Am Heart J 152: 493 e491-498.
31. Cavalca V, Veglia F, Squellerio I, De Metrio M, Rubino M, et al. (2012) Circulating Levels of Dimethylarginines, Chronic Kidney Disease and Long-Term Clinical Outcome in Non-ST-Elevation Myocardial Infarction. PLoS One 7: e48499.
32. Kielstein JT, Salpeter SR, Bode-Boeger SM, Cooke JP, Fliser D, (2006) Symmetric dimethylarginine (SDMA) as endogenous marker of renal function-a meta-analysis. Nephrol Dial Transplant 21: 2446-2451.
33. Morris SM Jr, (2005) Arginine metabolism in vascular biology and disease. Vasc Med 10 (Suppl 1):: S83-87.
34. Kang ES, Cates TB, Harper DN, Chiang TM, Myers LK, et al. (2001) An enzyme hydrolyzing methylated inhibitors of nitric oxide synthase is present in circulating human red blood cells. Free Radic Res 35: 693-707.
35. Ozuyaman B, Grau M, Kelm M, Merx MW, Kleinbongard P, (2008) RBC NOS: regulatory mechanisms and therapeutic aspects. Trends Mol Med 14: 314-322.
36. Bohmer A, Beckmann B, Sandmann J, Tsikas D, (2012) Doubts concerning functional endothelial nitric oxide synthase in human erythrocytes. Blood 119: 1322-1323.
37. Kang ES, Ford K, Grokulsky G, Wang YB, Chiang TM, et al. (2000) Normal circulating adult human red blood cells contain inactive NOS proteins. J Lab Clin Med 135: 444-451.
38. Mehta JL, Mehta P, Li D, (2000) Nitric oxide synthase in adult red blood cells: vestige of an earlier age or a biologically active enzyme? J Lab Clin Med 135: 430-431.
39. Wu G, Morris SM Jr, (1998) Arginine metabolism: nitric oxide and beyond. Biochem J 336 (Pt 1):: 1-17.
40. Li H, Meininger CJ, Hawker JR Jr, Haynes TE, Kepka-Lenhart D, et al. (2001) Regulatory role of arginase I and II in nitric oxide, polyamine, and proline syntheses in endothelial cells. Am J Physiol Endocrinol Metab 280: E75-82.
41. Chicoine LG, Paffett ML, Young TL, Nelin LD, (2004) Arginase inhibition increases nitric oxide production in bovine pulmonary arterial endothelial cells. Am J Physiol Lung Cell Mol Physiol 287: L60-68.
42. Romero MJ, Platt DH, Tawfik HE, Labazi M, El-Remessy AB, et al. (2008) Diabetes-induced coronary vascular dysfunction involves increased arginase activity. Circ Res 102: 95-102.
43. Durante W, Johnson FK, Johnson RA, (2007) Arginase: a critical regulator of nitric oxide synthesis and vascular function. Clin Exp Pharmacol Physiol 34: 906-911.
44. Kosenko E, Tikhonova L, Suslikov A, Kaminsky Y, (2012) Impacts of lisinopril and lisinopril plus simvastatin on erythrocyte and plasma arginase, nitrite, and nitrate in hypertensive patients. J Clin Pharmacol 52: 102-109.
45. Tang WH, Wang Z, Cho L, Brennan DM, Hazen SL, (2009) Diminished global arginine bioavailability and increased arginine catabolism as metabolic profile of increased cardiovascular risk. J Am Coll Cardiol 53: 2061-2067.
46. Ludolph B, Bloch W, Kelm M, Schulz R, Kleinbongard P, (2007) Short-term effect of the HMG-CoA reductase inhibitor rosuvastatin on erythrocyte nitric oxide synthase activity. Vasc Health Risk Manag 3: 1069-1073.
47. Durak I, Burak Cimen MY, Kacmaz M, Goren D, Serdar Ozturk H, et al. (2001) Aspirin induces erythrocyte nitric oxide synthase activity in vivo. Clin Chim Acta 314: 265-267.
48. Cavalca V, Cighetti G, Bamonti F, Loaldi A, Bortone L, et al. (2001) Oxidative stress and homocysteine in coronary artery disease. Clin Chem 47: 887-892.
49. Dzau VJ, Antman EM, Black HR, Hayes DL, Manson JE, et al. (2006) The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation 114: 2850-2870.
50. Dhawan SS, Eshtehardi P, McDaniel MC, Fike LV, Jones DP, et al. (2011) The role of plasma aminothiols in the prediction of coronary microvascular dysfunction and plaque vulnerability. Atherosclerosis 219: 266-272.
51. Profumo E, Buttari B, Petrone L, Straface E, Gambardella L, et al. (2011) Redox imbalance of red blood cells impacts T lymphocyte homeostasis: implication in carotid atherosclerosis. Thromb Haemost 106: 1117-1126.